Cargando…
Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399958/ https://www.ncbi.nlm.nih.gov/pubmed/34451862 http://dx.doi.org/10.3390/ph14080765 |
_version_ | 1783745199888924672 |
---|---|
author | Janowski, Marcin Milewska, Małgorzata Zare, Peyman Pękowska, Aleksandra |
author_facet | Janowski, Marcin Milewska, Małgorzata Zare, Peyman Pękowska, Aleksandra |
author_sort | Janowski, Marcin |
collection | PubMed |
description | Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and dysfunctions of the essential chromatin-modifying factors. Hence, compounds that target DNA and histone modification pathways, the so-called epidrugs, constitute promising tools to treat NDs. Yet, targeting the entire epigenome might reveal insufficient to modify a chosen gene expression or even unnecessary and detrimental to the patients’ health. New technologies hold a promise to expand the clinical toolkit in the fight against NDs. (Epi)genome engineering using designer nucleases, including CRISPR-Cas9 and TALENs, can potentially help restore the correct gene expression patterns by targeting a defined gene or pathway, both genetically and epigenetically, with minimal off-target activity. Here, we review the implication of epigenetic machinery in NDs. We outline syndromes caused by mutations in chromatin-modifying enzymes and discuss the functional consequences of mutations in regulatory DNA in NDs. We review the approaches that allow modifying the (epi)genome, including tools based on TALENs and CRISPR-Cas9 technologies, and we highlight how these new strategies could potentially change clinical practices in the treatment of NDs. |
format | Online Article Text |
id | pubmed-8399958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83999582021-08-29 Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue Janowski, Marcin Milewska, Małgorzata Zare, Peyman Pękowska, Aleksandra Pharmaceuticals (Basel) Review Neurological disorders (NDs) comprise a heterogeneous group of conditions that affect the function of the nervous system. Often incurable, NDs have profound and detrimental consequences on the affected individuals’ lives. NDs have complex etiologies but commonly feature altered gene expression and dysfunctions of the essential chromatin-modifying factors. Hence, compounds that target DNA and histone modification pathways, the so-called epidrugs, constitute promising tools to treat NDs. Yet, targeting the entire epigenome might reveal insufficient to modify a chosen gene expression or even unnecessary and detrimental to the patients’ health. New technologies hold a promise to expand the clinical toolkit in the fight against NDs. (Epi)genome engineering using designer nucleases, including CRISPR-Cas9 and TALENs, can potentially help restore the correct gene expression patterns by targeting a defined gene or pathway, both genetically and epigenetically, with minimal off-target activity. Here, we review the implication of epigenetic machinery in NDs. We outline syndromes caused by mutations in chromatin-modifying enzymes and discuss the functional consequences of mutations in regulatory DNA in NDs. We review the approaches that allow modifying the (epi)genome, including tools based on TALENs and CRISPR-Cas9 technologies, and we highlight how these new strategies could potentially change clinical practices in the treatment of NDs. MDPI 2021-08-04 /pmc/articles/PMC8399958/ /pubmed/34451862 http://dx.doi.org/10.3390/ph14080765 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Janowski, Marcin Milewska, Małgorzata Zare, Peyman Pękowska, Aleksandra Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title | Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title_full | Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title_fullStr | Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title_full_unstemmed | Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title_short | Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue |
title_sort | chromatin alterations in neurological disorders and strategies of (epi)genome rescue |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399958/ https://www.ncbi.nlm.nih.gov/pubmed/34451862 http://dx.doi.org/10.3390/ph14080765 |
work_keys_str_mv | AT janowskimarcin chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue AT milewskamałgorzata chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue AT zarepeyman chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue AT pekowskaaleksandra chromatinalterationsinneurologicaldisordersandstrategiesofepigenomerescue |